Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

for the first quarter of 2010. The decline for SG&A results from lower compensation and market research expenses during the quarter.  
  • Cash and cash equivalents were $73.8 million as of March 31, 2011, compared with $83.3 million as of December 31, 2010 and $55.2 million as of March 31, 2010. Net cash burn for the first quarter of 2011 was approximately $9.4 million.
  • For 2011, management anticipates total operating expenses will be slightly higher than those reported for 2010, which were approximately $68 million. The increase for operating expense is expected to arise from costs associated with additional activities related to clinical trials and manufacturing. The company continues to expect net cash burn of $47 to $52 million for the year 2011.

  • Upcoming Corporate and Scientific PresentationsHalozyme representatives are scheduled to present at the following events:

  • Bank of America Merrill Lynch Health Care Conference in Las Vegas, May 12, 2011 at 11:10 a.m. PDT (2:10 p.m. EDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for six months after the event.
  • American Diabetes Association Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has been notified of acceptance for two presentations of results and data from its Ultrafast Insulin program.

  • Conference CallHalozyme management will host a conference call and webcast on May 6, 2011 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
    (Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
    (Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
    (Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
    Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
    ... Medical, Inc., a medical device,company that has developed ... aneurysms, announced today that they have successfully raised ... Valor,s Chief,Executive Officer, Clark Adams stated, "Valor,s Board ... that will be used to complete,clinical trials needed ...
    ... 6 NutraCea (OTC Bulletin Board:,NTRZ), a world ... and,technology announced today that it has appointed Olga ... Todd Crow, in accordance with,his previously announced intentions, ... a consulting and advisory capacity., Ms. Hernandez-Longan ...
    ... loss narrows on higher revenue due to Roche milestone -, ... ) today announced results from operations for the third,quarter and ... for the third quarter of 2008 of $12.5 million, or ... or $0.66 per share, in the third,quarter of 2007., ...
    Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 9
    (Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
    (Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
    (Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
    Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
    ... Society for Microbiology (ASM) ICAAC Young Investigator Award ... University of Minnesota, Minneapolis. Sponsored by Merck U.S. ... for research excellence in microbiology and infectious diseases. ... the immunological memory of bacterial and viral pathogens ...
    ... Ohio -- Engineers at Ohio State University have found a ... might someday replace gasoline in automobiles. The process improves ... fermentation tank. Normally, bacteria could only produce a certain ... for every liter of water in the tank -- before ...
    ... Blacksburg, Va. -- After engineers and scientists at Virginia Tech, ... water, Michael Phelps may find he still has a few ... ,The remarkable ability of fish to maneuver in ... to accelerate in a seemingly effortless fashion has researchers wondering ...
    Cached Biology News:Researchers boost production of biofuel that could replace gasoline 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3
    ... Microplate Luminometer has been designed,for the ... for,all measurements of glow and flash ... the light remain nearly constant,over a ... as for very fast reactions,requiring at ...
    ... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
    ... Plasmid-Based Deletion Machine is based on the ... developed by Goryshin and Reznikoff, and by ... families of deletions and inversions by intramolecular ... transposon-containing plasmid vector. Although most researchers will ...
    ... knockout or alter genes on the E.coli ... recombination allows the exchange of genetic information in ... An FRT-flanked kanamycin resistance marker cassette is supplied ... replace a gene on the E.coli ...
    Biology Products: